Spectral AI (Spectral AI) Cash, Cash Equivalents, Marketable Securities : $10.16 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Cash, Cash Equivalents, Marketable Securities?

Spectral AI's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($7.35 Mil) to Dec. 2023 ($4.79 Mil) but then increased from Dec. 2023 ($4.79 Mil) to Mar. 2024 ($10.16 Mil).

Spectral AI's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($16.12 Mil) to Dec. 2022 ($14.17 Mil) and declined from Dec. 2022 ($14.17 Mil) to Dec. 2023 ($4.79 Mil).

Spectral AI Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Spectral AI's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Cash, Cash Equivalents, Marketable Securities Chart

Spectral AI Annual Data

Trend

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

16.12

14.17

4.79

Spectral AI Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			14.17	10.32	7.35	4.79	10.16

Spectral AI Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Spectral AI (NAS:MDAI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Spectral AI Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Spectral AI's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201

Website

https://www.spectralmd.com

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.

Executives

John Michael Dimaio	10 percent owner	6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p.	10 percent owner	2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton	director	RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b.	director	13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher	officer: Chief Scientist	6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler	officer: Chief Financial Officer	8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan	director, officer: CHIEF EXECUTIVE OFFICER	3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone	officer: GENERAL COUNSEL	1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos	officer: CHIEF OPERATING OFFICER	5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai	director	10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr.	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg	10 percent owner	73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260